US2016122437A1PendingUtilityA1

Antibodies to matrix metalloproteinase 9

57
Assignee: GILEAD BIOLOGICS INCPriority: Aug 27, 2010Filed: Jan 11, 2016Published: May 5, 2016
Est. expiryAug 27, 2030(~4.1 yrs left)· nominal 20-yr term from priority
Inventors:Scott Alan MccauleyMaria Vaysberg
A61P 9/00A61P 43/00A61P 35/04A61P 35/00A61P 29/00C07K 2317/92Y10S435/975C07K 2317/33C07K 2317/34C07K 2317/56C07K 2317/565C07K 16/40C07K 2317/24A61K 39/395C07K 2317/76
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated matrix metalloproteinase 9 (MMP9) binding protein, comprising:
 an immunoglobulin heavy chain polypeptide, or functional fragment thereof, and   an immunoglobulin light chain polypeptide, or functional fragment thereof,   wherein the MMP9 binding protein specifically binds to an to epitope of human MMP9 comprising amino acid residues R162, E111, D113, and 1198.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.